Ipatasertib
As of the edition of 20 October 2026, Ipatasertib is a small molecule: in active development; acts on AKT1, AKT2 and AKT3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2032
- Kind
- Small molecule
- Registered trials
- 53, 4 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Urinary and reproductive; Lungs and airways; Pregnancy and women's health; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 16 | 11 | 3 | 2 |
| Phase 2 | 32 | 12 | 16 | 2 |
| Phase 3 | 5 | 3 | 2 | 0 |
| All trials | 53 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Roche | Lead sponsor of trials | 2010 to now |